- Home
- SWIM vs ETNB Comparison
SWIM vs ETNB Comparison
Compare SWIM & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- ETNB
- Stock Information
- Founded
- SWIM 1956
- ETNB 2018
- Country
- SWIM United States
- ETNB United States
- Employees
- SWIM N/A
- ETNB N/A
- Industry
- SWIM Plastic Products
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- ETNB Health Care
- Exchange
- SWIM Nasdaq
- ETNB Nasdaq
- Market Cap
- SWIM 751.3M
- ETNB 867.4M
- IPO Year
- SWIM 2021
- ETNB 2019
- Fundamental
- Price
- SWIM $5.72
- ETNB $7.93
- Analyst Decision
- SWIM Hold
- ETNB Buy
- Analyst Count
- SWIM 5
- ETNB 7
- Target Price
- SWIM $5.62
- ETNB $30.33
- AVG Volume (30 Days)
- SWIM 695.0K
- ETNB 901.8K
- Earning Date
- SWIM 11-05-2024
- ETNB 11-07-2024
- Dividend Yield
- SWIM N/A
- ETNB N/A
- EPS Growth
- SWIM N/A
- ETNB N/A
- EPS
- SWIM 0.10
- ETNB N/A
- Revenue
- SWIM $512,114,000.00
- ETNB N/A
- Revenue This Year
- SWIM N/A
- ETNB N/A
- Revenue Next Year
- SWIM $5.14
- ETNB $133.30
- P/E Ratio
- SWIM $57.51
- ETNB N/A
- Revenue Growth
- SWIM N/A
- ETNB N/A
- 52 Week Low
- SWIM $2.11
- ETNB $7.00
- 52 Week High
- SWIM $7.33
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- SWIM 39.61
- ETNB 42.09
- Support Level
- SWIM $5.40
- ETNB $9.00
- Resistance Level
- SWIM $6.16
- ETNB $10.01
- Average True Range (ATR)
- SWIM 0.34
- ETNB 0.80
- MACD
- SWIM -0.09
- ETNB -0.10
- Stochastic Oscillator
- SWIM 24.32
- ETNB 8.52
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).